GLP-1semaglutidenaiondiabetic retinopathytype 2 diabetes

Single-center cohort records no NAION cases in 100 semaglutide patients

Over 299 person-years at Rajavithi Hospital, proliferative diabetic retinopathy appeared in 10% and macular edema in 3% of the type 2 diabetes cohort.

By Maren Holt · Senior Reporter, GLP-1

Oct 11 20:00 ETSource: Clinical ophthalmology (Auckland, N.Z.)

The wire

01Retrospective review of 100 semaglutide-treated type 2 diabetes patients found zero non-arteritic anterior ischemic optic neuropathy events over 299 person-years, crude incidence 0 per 1,000 person-years, 95% CI 0 to 6.17.
02NAION signals have driven label scrutiny of semaglutide; prescribers weighing eye risk get one more small data point, alongside a reminder to monitor retinopathy in patients with higher BMI and fasting glucose.
03Authors say the sample size precludes conclusions on NAION risk and call for larger prospective studies; the 13 patients with ocular complications already had worse baseline visual acuity.

From the source

Semaglutide Use and Risk of Diabetic Retinopathy and Non-Arteritic Anterior Ischemic Optic Neuropathy in Type 2 Diabetes: A Single-Center Retrospective Cohort Study
Clinical ophthalmology (Auckland, N.Z.) · 2026 · Kemchoknatee P, Pakaymaskul P, Piyawannarat N et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42890826/